Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of cefiderocol versus colistin for carbapenem-resistant gram-negative infections
CTR20221991Phase 3Completed
- Sponsor
- 不适用/ 平安盐野义有限公司
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cefiderocol in Gram-negative bacterial infection, hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Healthcare-associated pneumonia (HCAP), Intra-abdominal infection (IAI), sponsored by 不适用/ 平安盐野义有限公司. Started Nov 2022; status: completed.
02
Drugs
cefiderocol
03
Conditions
Gram-negative bacterial infectionhospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Healthcare-associated pneumonia (HCAP)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on CTR20221991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221991.